Pro Pharmaceuticals Inc.
Pro Pharmaceuticals Inc. is listed today as Galectin Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2016 | $3 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Sep 2016 | $2 M | Private placement after listing | Under $2 million | equity, options | SEC | |
| Dec 2010 | $2 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pro Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).
SEC Form D · Jan 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2017
That is all the official record says: Pro Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Pro Pharmaceuticals Inc. are on record.
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Gilbert S. Omenn | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Richard E. Uihlein | Person | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.
Largest shareholders today
Institutions holding Galectin Therapeutics Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$13 M3.35%
- Vanguard Capital Management LLC$8 M2.07%
- Geode Capital Management, LLC$5 M1.24%
- Osaic Holdings, Inc.$5 M1.20%
- State Street Corp$3 M0.79%
- Wealthspire Advisors, LLC$3 M0.72%
- Corient Private Wealth LP$2 M0.54%
- Marshall Wace, LLP$2 M0.46%
- Commonwealth Equity Services, LLC$2 M0.46%
- Northern Trust Corp$1 M0.37%
- Vanguard Portfolio Management LLC$1 M0.33%
- Vanguard Fiduciary Trust Co$1 M0.33%
- LPL Financial LLC$1 M0.28%
- Sovran Advisors, LLC$1 M0.25%
- Geneos Wealth Management Inc.$1 M0.24%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Harold H. Shlevin | Executive officer | Jan 2017 |
| Jack W Callicutt | Executive officer | Jan 2017 |
| Peter G Traber | Executive officer | Jan 2017 |
| Anatole C. Klyosov | Executive officer | Jan 2011 |
| Anthony D. Squeglia | Executive officer | Jan 2011 |
| Eliezer C. Zomer | Executive officer | Jan 2011 |
| Maureen D. Foley | Executive officer | Jan 2011 |
| Theodore D. Zucconi | Executive officer | Jan 2011 |
| Arthur R Greenberg | Director | Jan 2017 |
| Gilbert F Amelio | Director | Jan 2017 |
| Gilbert S Omenn | Director | Jan 2017 |
| James C Czirr | Director | Jan 2017 |
| John G. Mauldin | Director | Jan 2017 |
| Kevin D Freeman | Director | Jan 2017 |
| Marc G. Rubin | Director | Jan 2017 |
| Peter G Traber | Director | Jan 2017 |
| Steven G. Prelack | Director | Jan 2017 |
| Theodore H. Zuconni | Director | Jan 2017 |
| Jack W Callicutt | Director | Sep 2016 |
| Arthur R. Greenberg | Director | Jan 2011 |
| Gilbert F. Amelio | Director | Jan 2011 |
| James C. Czirr | Director | Jan 2011 |
| Jerald F. Rome | Director | Jan 2011 |
| Peter D. Traber | Director | Jan 2011 |
| Rod D. Martin | Director | Jan 2011 |
| S. Colin Neill | Director | Jan 2011 |
| Steven F. Prelack | Director | Jan 2011 |
| Theodore D. Zucconi | Director | Jan 2011 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.